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The use of placebos in clinical trials has major policy
implications for ethical conduct across all of medicine and is
relevant to clinicians, patients, drug development, and regulatory
agencies. This article focuses on the use of placebos in relapse
prevention studies in schizophrenia. However, the issues
discussed are similar to those encountered in many other clinical
trial situations. These include underestimating the risk of harm
associated with trial participation, the risk of coercion,
insufficient awareness of the risks by participants, and the risk
of loss of trust between the patient and doctor.
While the debate around using placebos in clinical trials of
schizophrenia is long running, several developments make it
imperative to readdress the topic. Firstly, new research has
reported deleterious effects of relapse,1 challenging the previous
assumption that relapse is not associated with a risk of lasting
harm. Secondly, new questions have been raised about the need
for maintenance treatment in schizophrenia.2 Thirdly, ethical
standards have evolved, with reduced tolerance of exposure of
participants to risk and greater respect of patient autonomy.
Finally, and most importantly, recent publications from both
the European Medicines Agency and US Food and Drug
Administration continue to encourage the use of placebos in
schizophrenia trials.
Maintenancemedication for schizophrenia
The place of maintenance antipsychotic treatment in
schizophrenia has been questioned for two reasons.2 The drugs
have potentially serious adverse effects, and preliminary and
uncontrolled evidence suggests that in some patients gradual
dose reduction and, where feasible, discontinuation may be
associated with better long term outcome.3 However, stopping
antipsychotic treatment is associated with very high rates of
relapse, even after a single episode of psychosis.4Relapses may
be associated with undue patient suffering, detrimental effects
on social and vocational function, delayed time to treatment
response, emergent treatment refractoriness, and reduction in
brain volume.1 Furthermore, predictors of relapse are unreliable,
measures to identify early signs of relapse are not always
effective, and rescue interventions may not always prevent
recurrence of severe illness.5 These concerns, together with the
fact that the effectiveness of maintenance antipsychotic
medication is one of the best documented findings in psychiatry,6
indicate that the benefits of maintenance treatment clearly
outweigh the risks.
The efficacy and safety of antipsychotics for maintenance
treatment of schizophrenia have been established through
clinical development programmes, of which the placebo
controlled, randomised, controlled trial has been a key
component. Given the high rates of relapse associated with
placebo treatment, it is not surprising that concerns have been
raised regarding the risks to participants exposed to placebo in
randomised trials.7 8The topic was discussed at a full symposium
of 4th Schizophrenia International Research Society Conference
in April 2014.
Unlike in clinical settings, where the decision to discontinue
treatment is largely patient driven, in trials the decision to
withhold active treatment is instigated by clinicians. This is in
direct contrast to the usual focus of clinicians on promoting
adherence to treatment.9 Risk to trial participants is likely to be
greatest in trials of maintenance treatment or relapse prevention,
where patients, once stabilised, are switched to placebo until
sufficient relapse events have occurred to be able to show a
treatment effect. Indeed, the absolute risk difference for
antipsychotics versus placebo in relapse prevention studies is
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more than double that in acute trials.10 Despite these concerns,
current practice permits the use of placebos in such settings and
various stakeholders promote these trials.
Ethical position
The World Medical Association’s Declaration of Helsinki
regards the use of placebos as acceptable in studies where there
is no proved intervention, or where compelling and scientifically
sound methodological reasons exist for the use of placebos to
determine efficacy or safety of an intervention, and where
patients who receive placebos will not be exposed to any risk
of serious or irreversible harm. The declaration states that
extreme care should be taken to avoid abuse of this option, and
that the interest of science and society should never take
precedence over considerations related to the wellbeing of
individual patients.11
The International Conference on Harmonisation guideline on
choice of control group12 considers a placebo control to be
generally inappropriate when an available treatment is known
to prevent serious harm in the study population. The document
specifies that there are occasional exceptions, such as when
standard therapy has toxicity so severe that many patients have
refused to receive it.
What the regulatory authorities say
Regulatory authorities in North America and the European
Union continue to encourage placebo controls in relapse
prevention studies for the licensing of new drugs. The EMA’s
recent guidelines for trials of new treatments for schizophrenia
states that, to show that a treatment maintains effectiveness over
time, the inclusion of a placebo arm is possible and appropriate
in a randomised withdrawal study (the standard design in
placebo controlled relapse prevention studies) as long as it is
appropriately designed and conducted.13 The document
emphasises that these studies need to be conducted in highly
controlled settings, with appropriate safeguards. It states that
in this setting the benefits of a placebo arm will generally
over-ride ethical reservations and that there should not be ethical
problems if patients who relapse receive immediate active
treatment.13
A draft guidance on enrichment strategies for clinical trials by
the FDA describes the randomised withdrawal design as a way
to establish long term effectiveness of drugs when protracted
use of a placebo would not be acceptable. In this design the
study population receives active treatment for an extended period
and those who respond enter a blinded, randomised treatment
withdrawal phase for a short duration. Patients are withdrawn
from the study if their symptoms recur, thereby minimising
exposure to placebo.14
Arguments for continued use of placebo
There is a moral imperative to guard against ineffectual
treatments being approved for use in clinical practice. A
comparison between the investigational drug and placebo is
considered the most powerful method of establishing efficacy
and its use in randomised trials in schizophrenia has been
regarded as both ethically and scientifically justifiable when
supported by sound methodological considerations and its use
does not expose participants to excessive risks of harm.15 The
ongoing inclusion of placebos in relapse prevention studies has
been justified on the basis of there being no clear evidence of
increased risk of persistent morbidity or mortality, and because
alternative study designs may not be as good at demonstrating
efficacy and tolerability. It has been argued that use of placebos
can be considered to be safe and ethical based on three premises:
• Available empirical evidence indicates no increased risk
of severe harm or long term morbidity after exposure to
placebos
• The belief that clinical measures can be put in place to
effectively detect early symptoms and prevent serious
relapse
• The likelihood that from a statistical perspective fewer
relapses would be necessary to detect a positive outcome
with placebos rather than with an active comparator16
Our concerns
We believe that all three of these assumptions may be flawed.
Relapses can cause lasting harm, and “rescue” interventions in
trials are not always effective in averting relapse. Furthermore,
the statistical advantage of placebo trials requiring fewer relapse
events may be nullified by the higher dropout rates associated
with these studies.
For patients requiring maintenance treatment, exposure to
placebos is associated with increased risk of relapse and
consequently a risk of undue harm. Inclusion of a placebo arm
conflicts with the principle of clinical equipoise (when there is
uncertainty whether a treatment will be beneficial), which
requires the use of best available treatment as the control in a
randomised trial. It also conflicts with the principle of
beneficence, which requires that physicians should act in the
best interest of each patient. Physicians often experience conflict
of interests when participating in clinical trials, having to balance
the interests of patients, academic reward, and, in the case of
industry sponsored studies, financial incentives. ThoughMiller
and Brody argued that clinical equipoise ignores the distinction
between clinical trials and treatment, and that placebo controls
are ethically justifiable in some situations, they mention placebo
controlled trials in schizophrenia as an example where it would
be difficult to justify the risks of symptom exacerbation for
those randomised to placebos.15
There are alsomisgivings from a patient perspective, particularly
around consent. In clinical settings it is difficult for people with
schizophrenia to agree to take antipsychotics because of factors
such as society’s prejudice about psychiatric medication,
deleterious side effects, and the person not having a strong
enough bond of trust with their prescriber. The use of placebos
in clinical trials runs the risk of fracturing trust, which is the
cornerstone of the therapeutic relationship, with serious
implications for ongoing treatment.
In addition to the ethical concerns, scientific considerations
diminish the power of placebo controlled trials to establish
efficacy. There is a risk of selection bias, both of patients and
of investigators. Patients who are sceptical about the long term
use of antipsychotics are more likely to agree to
participate—indeed, fear of relapse was cited as one of the main
reasons for patients not participating in a placebo controlled
study.17 Also, many investigators refuse to participate in such
trials, citing ethical concerns as the reasons.18A further concern
is that the high dropout rates in clinical trials using placebo
controls19 reduce their statistical power. Also, there is a risk of
unblinding as patients receiving placebos may sense that they
are no longer taking an active medication. Finally, there is
evidence, albeit weak, that sudden discontinuation of active
treatment might provoke a psychosis in some patients, over and
above the risk from the underlying illness.2 More research is
required, including trials incorporating gradual and careful
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withdrawal of medication or further exploration of a low dose
option, where clinical equipoise exists and where contingencies
are arranged to minimise any harms from relapse.
We believe that a distinction needs to be drawn between short
term efficacy and relapse prevention trials. Concerns regarding
the use of placebos are greatest in relapse prevention trials.
Other study designs such as the use of an active control with a
non-inferiority design represent a reasonable alternative to
placebo controlled trials.8 20 A precedent is already established,
as several widely used antipsychotics are registered for
maintenance treatment for schizophrenia without placebo
controlled relapse prevention studies having been conducted,
most notably risperidone (both oral and long acting injectable),
amisulpride, and olanzapine pamoate.7Most placebo controlled
relapse prevention trials have shown efficacy for the tested drug.
For new drugs with a similar mechanism of action to those
already approved it is therefore sufficient to rely on the short
term efficacy results, the data on existing drugs, and
maintenance treatment design strategies that do not use placebos.
No evidence of harm or evidence of no
harm
The literature investigating the consequences of withholding
treatment and the consequences of relapse in schizophrenia is
inadequate.7 There are few well designed longitudinal studies
assessing the psychosocial and biological consequences of
exposure to placebos or relapse. Without such studies it cannot
be assumed that patients experiencing relapses are not at risk
of severe or lasting harm. No evidence of harm is different from
evidence of no harm,21 and the burden must be to show no harm.
There is cause for concern that a real risk exists.
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Summary points
Concerns regarding the use of placebos in schizophrenia are greatest in relapse prevention trials
Measures to identify early signs of relapse are not always effective, and rescue interventions may not always be able to prevent recurrence
Research is limited but there is sufficient cause for concern that withdrawing treatment risks undue patient harm
Non-inferiority comparative study designs represent a reasonable alternative to placebo controlled trials
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